Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.

Profluent, which will design recombinases for the collaboration, could receive up to $2.25 billion in the deal.

Recent advances in genomics, genome editing, and imaging technologies have revealed that neural activity can rapidly alter chromatin accessibility, ...

DNAWORKS’ world premiere production of “The Secret Sharer" centers queer joy while SpeakEasy Stage Company’s “Swept Away” is ...

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionately impacts ...

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting ...

When leading Chinese automaker Chery Automobile recently swept five of the 2025 J.D. Power awards, the auto industry's most ...

A New Class of Smartphones Emerges as NOTE 60 Ultra Nears Nigeria Launch …Supercar-Inspired Design Meets Satellite ...

BMW has given its seventh-generation 7 Series an extensive makeover, adding a plusher cabin, new powertrains and more EV ...

Sneaker culture moves fast, and if you blink, you miss it. One day a silhouette sits on the shelf waiting for the right ...

The future of medicine is being quietly built in an unassuming Perth lab by an impressive group that is flying under the ...

A man has been sentenced to 20 years in prison in Oregon for the death of his then-girlfriend in a 1980s cold case that was recently reopened.